Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?

Medeni S. S., Turkyilmaz D., Acar C., Sevindik O. G., YÜKSEL F., Piskin O., ...Daha Fazla

TURKISH JOURNAL OF HEMATOLOGY, cilt.35, sa.4, ss.271-276, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.4274/tjh.2018.0071
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.271-276
  • Anahtar Kelimeler: Multiple myeloma, Autologous transplantation, Multiple reinfusion days, MYELOMA PATIENTS, AUTOLOGOUS TRANSPLANTATION, BLOOD, RECOVERY, OLDER, AGE, CHEMOTHERAPY, EXPERIENCE, MANAGEMENT, RELEVANCE
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: High-doses of melphalan treatment with autologous stem cell transplantation in multiple myeloma (MM) remains a major treatment modality in suitable patients. A minimal dose of 2x10(6)/kg CD34+ cells is preferred to achieve engraftment. Some patients need multiple leukapheresis procedures to achieve the necessary number of CD34+ cells, but this can cause a high volume of stem cell product that cannot be given in a single day. Whether or not the number of infusion days affects engraftment has not been studied before. We aimed to evaluate the impact of reinfusion of stem cells on multiple days on engraftment results.